News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: October 5, 2021
“These subtypes represent a potentially powerful tool for personalized therapeutic decision-making that may improve outcomes in metastatic mCRPC,” ...
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: September 22, 2021
A study published in JAMA Dermatology sheds light on which patients with BCC may be appropriate candidates for watchful waiting.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: August 11, 2021
Rates of heart and lung complications very low, with no increased non–breast cancer related mortality with radiation procedure.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: August 9, 2021
“Because cure rates now exceed 90%, using neurotoxic drugs in non–risk-adapted protocols is unacceptable and a pa...
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: August 9, 2021
But for patients with higher baseline cardiopulmonary risk factors, lower mean heart doses should be used.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: July 20, 2021
The problem is that about 20% of patients become allergic to the standard option, asparaginase derived from Escherichia coli.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: July 13, 2021
Regulators and policymakers are “keenly aware that physicians and patients alike are anxious to get going and sta...
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: July 6, 2021
New results show no difference in disease-free survival, distant disease-free survival, and overall survival.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: June 29, 2021
This study “provides the evidence needed to reassure women and couples seeking fertility treatments.”
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: June 10, 2021
The drug is a monoclonal antibody that blocks programmed cell dealth protein 1 (PD-1).
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: November 17, 2020
Pregnancy after treatment for breast cancer with BRCA mutations is safe, researchers say.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: November 16, 2020
This is the first breast cancer indication for pembrolizumab.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: August 31, 2020
This test is not endorsed by the American Academy of Dermatology or National Comprehensive Cancer Network outside of studies.
